KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to -$1.15.

  • Xenon Pharmaceuticals' EPS (Basic) fell 4197.53% to -$1.15 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.89, marking a year-over-year decrease of 3794.33%. This contributed to the annual value of -$3.01 for FY2024, which is 1019.39% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its EPS (Basic) stood at -$1.15 for Q3 2025, which was down 4197.53% from -$1.07 recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year EPS (Basic) high stood at -$0.35 for Q1 2022, and its period low was -$1.15 during Q3 2025.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.63 (2023), whereas its average is -$0.67.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' EPS (Basic) plummeted by 1039378.46% in 2021, and later soared by 1666.67% in 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.48 in 2021, then fell by 18.75% to -$0.57 in 2022, then fell by 12.28% to -$0.64 in 2023, then plummeted by 59.55% to -$1.02 in 2024, then fell by 12.62% to -$1.15 in 2025.
  • Its EPS (Basic) stands at -$1.15 for Q3 2025, versus -$1.07 for Q2 2025 and -$0.83 for Q1 2025.